Warnke C - Search Results

1

Ocrelizumab Extended Interval Dosing in Multiple Sclerosis in Times of COVID-19.

Rolfes L, Pawlitzki M, Pfeuffer S, Nelke C, Lux A, Pul R, Kleinschnitz C, Kleinschnitz K, Rogall R, Pape K, Bittner S, Zipp F, Warnke C, Goereci Y, Schroeter M, Ingwersen J, Aktas O, Klotz L, Ruck T, Wiendl H, Meuth SG. Rolfes L, et al. Among authors: warnke c. Neurol Neuroimmunol Neuroinflamm. 2021 Jul 14;8(5):e1035. doi: 10.1212/NXI.0000000000001035. Print 2021 Sep. Neurol Neuroimmunol Neuroinflamm. 2021. PMID: 34261812 Free PMC article.

2

Identification of targets and new developments in the treatment of multiple sclerosis--focus on cladribine.

Warnke C, Wiendl H, Hartung HP, Stüve O, Kieseier BC. Warnke C, et al. Drug Des Devel Ther. 2010 Jul 21;4:117-26. doi: 10.2147/dddt.s6627. Drug Des Devel Ther. 2010. PMID: 20689698 Free PMC article. Review.

3

CD34+ progenitor cells mobilized by natalizumab are not a relevant reservoir for JC virus.

Warnke C, Smolianov V, Dehmel T, Andrée M, Hengel H, Zohren F, Arendt G, Wiendl H, Haas R, Hartung HP, Adams O, Kieseier BC. Warnke C, et al. Mult Scler. 2011 Feb;17(2):151-6. doi: 10.1177/1352458510385834. Epub 2010 Nov 15. Mult Scler. 2011. PMID: 21078695

4

[Progressive multifocal leukoencephalopathy under natalizumab. Initial possibilities for risk stratification?].

Warnke C, Adams O, Gold R, Hartung HP, Hohlfeld R, Wiendl H, Kieseier BC. Warnke C, et al. Nervenarzt. 2011 Apr;82(4):475-80. doi: 10.1007/s00115-010-3091-8. Nervenarzt. 2011. PMID: 21240604 German.

5

[Risk stratification of progressive multifocal leukoencephalopathy under natalizumab: recommendations for JC virus serology].

Warnke C, Adams O, Hartung HP, Gold R, Hemmer B, Hohlfeld R, Stangel M, Zipp F, Wiendl H, Kieseier BC. Warnke C, et al. Nervenarzt. 2011 Oct;82(10):1314-9. doi: 10.1007/s00115-011-3319-2. Nervenarzt. 2011. PMID: 21656322 German. No abstract available.

6

Cladribine as a therapeutic option in multiple sclerosis.

Warnke C, Leussink VI, Goebels N, Aktas O, Boyko A, Kieseier BC, Hartung HP. Warnke C, et al. Clin Immunol. 2012 Jan;142(1):68-75. doi: 10.1016/j.clim.2011.05.009. Epub 2011 Jun 1. Clin Immunol. 2012. PMID: 21733757 Review.

7

[Alemtuzumab: a further option for treatment of multiple sclerosis].

Menge T, Kieseier BC, Warnke C, Aktas O, Hartung HP. Menge T, et al. Among authors: warnke c. Nervenarzt. 2012 Apr;83(4):487-501. doi: 10.1007/s00115-011-3393-5. Nervenarzt. 2012. PMID: 22038387 German.

8

An assay to quantify species-specific anti-JC virus antibody levels in MS patients.

Warnke C, Pawlita M, Dehmel T, Posevitz-Fejfar A, Hartung HP, Wiendl H, Kieseier BC, Adams O. Warnke C, et al. Mult Scler. 2013 Aug;19(9):1137-44. doi: 10.1177/1352458513475489. Epub 2013 Feb 6. Mult Scler. 2013. PMID: 23388163

9

[Teriflunomide for treatment of multiple sclerosis].

Warnke C, Meyer Zu Hörste G, Menge T, Stüve O, Hartung HP, Wiendl H, Kieseier BC. Warnke C, et al. Nervenarzt. 2013 Jun;84(6):724-31. doi: 10.1007/s00115-013-3779-7. Nervenarzt. 2013. PMID: 23695001 Review. German.

10

L-selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients.

Schwab N, Schneider-Hohendorf T, Posevitz V, Breuer J, Göbel K, Windhagen S, Brochet B, Vermersch P, Lebrun-Frenay C, Posevitz-Fejfár A, Capra R, Imberti L, Straeten V, Haas J, Wildemann B, Havla J, Kümpfel T, Meinl I, Niessen K, Goelz S, Kleinschnitz C, Warnke C, Buck D, Gold R, Kieseier BC, Meuth SG, Foley J, Chan A, Brassat D, Wiendl H. Schwab N, et al. Among authors: warnke c. Neurology. 2013 Sep 3;81(10):865-71. doi: 10.1212/WNL.0b013e3182a351fb. Epub 2013 Aug 7. Neurology. 2013. PMID: 23925765

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

166 results

Search Page